BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026.
World J Virol. Mar 25, 2026; 15(1): 118274
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.118274
Table 3 Comparison of comorbidities in survivors vs non-survivors, n (%)
Variable2 months (n = 230)
6 months (n = 198)
Survivors (n = 134)Non-survivors (n = 96)
SMD (95%CI)
Survivors
Non-survivorsSMD (95%CI)
Diabetes mellitus44 (33.0)43 (45.0)-0.25 (-0.51, 0.02)22 (30.0)54 (44.0)-0.29 (-0.58, 0.00)
Hypertension85 (63.0)63 (66.0)-0.05 (-0.31, 0.22)47 (64.0)79 (64.0)0.00 (-0.29, 0.28)
Coronary artery disease22 (16.0)21 (22.0)-0.14 (-0.40, 0.12)11 (15.0)27 (22.0)-0.18 (-0.47, 0.11)
Chronic kidney disease15 (11.0)11 (11.0)-0.01 (-0.27, 0.25)6 (8.1)17 (14.0)-0.18 (-0.47, 0.11)
Chronic obstructive pulmonary disease15 (11.0)19 (20.0)-0.24 (-0.50, 0.02)8 (11.0)21 (17.0)-0.18 (-0.47, 0.11)


Write to the Help Desk